EAACI Task force Clinical epidemiology of anaphylaxis: experts' perspective on the use of adrenaline autoinjectors in Europe

被引:15
|
作者
Kraft, Magdalena [1 ,2 ,3 ,4 ]
Dolle-Bierke, Sabine [1 ,2 ,3 ,4 ]
Turner, Paul J. [5 ]
Muraro, Antonella [6 ]
Fernandez-Rivas, Montserrat [7 ]
Grabenhenrich, Linus [1 ,2 ,3 ,4 ,8 ]
Worm, Margitta [1 ,2 ,3 ,4 ]
机构
[1] Charite Univ Med Berlin, Div Allergy & Immunol, Dept Dermatol Venerol & Allergol, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Berlin Inst Hlth, Berlin, Germany
[5] Imperial Coll London, Natl Heart & Lung Inst, Sect Inflammat Repair & Dev, London, England
[6] Padua Gen Univ Hosp, Food Allergy Referral Ctr, Dept Women & Child Hlth, Padua, Italy
[7] Univ Complutense, Hosp Clin San Carlos, ARADyAL, Dept Allergy,IdISSC, Madrid, Spain
[8] Robert Koch Inst, Dept Infect Dis Epidemiol, Berlin, Germany
关键词
Anaphylaxis; Anaphylactic reaction; Adrenaline autoinjector; AAI; Epinephrine autoinjector; European Academy of Allergy and Clinical Immunology guidelines; European Medical Agency;
D O I
10.1186/s13601-020-00317-y
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background Worldwide, guidelines recommend the use of adrenaline autoinjectors (AAIs) for self-medication in patients who experience severe allergic reaction. The European Medical Agency recommends the prescription of two AAIs, which should be carried by patients at all times. The European Academy of Allergy and Clinical Immunology guidelines propose to prescribe a second AAI under some defined conditions. In the present study, we aimed to examine the adherence to these guidelines and prescription behavior of allergy experts regarding the number of AAIs prescribed for a given patient. Methods A standardized questionnaire was applied to the participants of the 5th International Conference of the Network of Online Registration for Anaphylaxis (NORA e. V.). Twenty-six experts (medical doctors with at least 2 years of experience in the field of anaphylaxis) answered the questions regarding the number of autoinjectors prescribed and the reasons influencing their decisions. Results Sixty-eight percent of the experts usually prescribed one AAI, while 32% prescribed two. The pediatricians and physicians with less experience tended to prescribe two autoinjectors more frequently. The experts were more likely to prescribe two adrenaline autoinjectors if the patient was a child, had a previous severe reaction, had mastocytosis, asthma, cardiovascular disease, or high body weight, or lived far from the emergency department. Conclusion Our data confirm the lack of consensus regarding the number of AAIs to prescribe. Despite the European Medical Agency recommendation, the majority of allergy experts prescribed one autoinjector per patient. However, under distinct circumstances (e.g. mastocytosis, asthma, excess body weight, a history of severe anaphylaxis, or restricted access to immediate emergency), experts tended to prescribe more AAIs, which is in accordance with the European Academy of Allergy and Clinical Immunology guidelines.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] European guidelines on the prevention of cardiovascular disease in clinical practice (2012 version). Fifth Joint Task Force of the European Society of Cardiology and other Societies on the Prevention of Cardiovascular Diseases in Clinical Practice (consisting of representatives of nine companies and invited experts)
    Perk, Joep
    De Backer, Guy
    Gohlke, Helmut
    Graham, Ian
    Reiner, Zeljko
    Verschuren, W. M. Monique
    Albus, Christian
    Benlian, Pascale
    Boysen, Gudrun
    Cifkova, Renata
    Deaton, Christi
    Ebrahim, Shah
    Fisher, Miles
    Germano, Giuseppe
    Hobbs, Richard
    Hoes, Arno
    Karadeniz, Sehnaz
    Mezzani, Alessandro
    Prescott, Eva
    Ryden, Lars
    Scherer, Martin
    Syvanne, Mikko
    Reimer, Wilma J. M. Scholte Op
    Vrints, Christiaan
    Wood, David
    Zamorano, Jose Luis
    Zannad, Faiez
    GIORNALE ITALIANO DI CARDIOLOGIA, 2013, 14 (05) : 328 - 392
  • [42] European guidelines on cardiovascular disease prevention in clinical practice -: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts) (vol 171, pg 145, 2003)
    De Backer, G
    Ambrosioni, E
    Borch-Johnsen, K
    Brotons, C
    Cifkova, R
    Dallongeville, J
    Ebrahim, S
    Faergeman, O
    Graham, I
    Mancia, G
    Cats, VM
    Orth-Gomér, K
    Perk, J
    Pyörälä, K
    Rodicio, JL
    Sans, S
    Sansoy, V
    Sechtem, U
    Silber, S
    Thomsen, T
    Wood, D
    ATHEROSCLEROSIS, 2004, 173 (02) : 379 - 391
  • [43] Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
    Angioni, D.
    Hansson, O.
    Bateman, R. J.
    Rabe, C.
    Toloue, M.
    Braunstein, J. B.
    Agus, S.
    Sims, J. R.
    Bittner, T.
    Carrillo, M. C.
    Fillit, H.
    Masters, C. L.
    Salloway, S.
    Aisen, P.
    Weiner, M.
    Vellas, B.
    Gauthier, S.
    EU US CTAD Task force, Mohammad
    Alam, John
    Algeciras-Schimnich, Alicia
    Andrieu, Sandrine
    Ballard, Clive
    Baruch, Amos
    Batrla, Richard
    Baudler, Monika
    Bell, Joanne
    Bozeat, Sasha
    Brooks, Dawn
    Brooks, Tricia
    Bullain, Szofia
    Burmeister, Jan
    Cho, Min
    Collins, Emily
    Cook, Gavin
    Cummings, Jeffrey
    Dague, Chris
    De Santi, Susan
    Doody, Rachelle
    Dunn, Billy
    Egan, Michael
    Eriksson, Sven
    Esquivel, Rianne
    Fagan, Tom
    Ferrell, Phyllis
    Gallagher, Michela
    Groenblad, Anna-Kaija
    Hains, Avis
    Hampel, Harald
    Hefting, Nanco
    Hendrix, Suzanne
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2023, 10 (03): : 418 - 425
  • [44] Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
    D. Angioni
    O. Hansson
    R. J. Bateman
    C. Rabe
    M. Toloue
    J. B. Braunstein
    S. Agus
    J. R. Sims
    T. Bittner
    M. C. Carrillo
    H. Fillit
    C. L. Masters
    S. Salloway
    P. Aisen
    M. Weiner
    B. Vellas
    S. Gauthier
    Susan Abushakra
    Mohammad Afshar
    John Alam
    Alicia Algeciras-Schimnich
    Sandrine Andrieu
    Clive Ballard
    Amos Baruch
    Richard Batrla
    Monika Baudler
    Joanne Bell
    Sasha Bozeat
    Dawn Brooks
    Tricia Brooks
    Szofia Bullain
    Jan Burmeister
    Min Cho
    Emily Collins
    Gavin Cook
    Jeffrey Cummings
    Chris Dague
    Susan De Santi
    Rachelle Doody
    Billy Dunn
    Michael Egan
    Sven Eriksson
    Rianne Esquivel
    Tom Fagan
    Phyllis Ferrell
    Michela Gallagher
    Anna-Kaija Grönblad
    Avis Hains
    Harald Hampel
    Nanco Hefting
    The Journal of Prevention of Alzheimer's Disease, 2023, 10 : 418 - 425
  • [45] Framework and metrics for the clinical use and implementation of artificial intelligence algorithms into endoscopy practice: recommendations from the American Society for Gastrointestinal Endoscopy Artificial Intelligence Task Force
    Parasa, Sravanthi
    Repici, Alessandro
    Berzin, Tyler
    Leggett, Cadman
    Gross, Seth A.
    Sharma, Prateek
    GASTROINTESTINAL ENDOSCOPY, 2023, 97 (05) : 815 - +
  • [46] Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping:: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN
    Carlsen, K. H.
    Anderson, S. D.
    Bjermer, L.
    Bonini, S.
    Brusasco, V.
    Canonica, W.
    Cummiskey, J.
    Delgado, L.
    Del Giacco, S. R.
    Drobnic, F.
    Haahtela, T.
    Larsson, K.
    Palange, P.
    Popov, T.
    van Cauwenberge, P.
    ALLERGY, 2008, 63 (05) : 492 - 505
  • [47] Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report
    Joudrey, Paul J.
    Bart, Gavin
    Brooner, Robert K.
    Brown, Lawrence
    Dickson-Gomez, Julie
    Gordon, Adam
    Kawasaki, Sarah S.
    Liebschutz, Jane M.
    Nunes, Edward
    McCarty, Dennis
    Schwartz, Robert P.
    Szapocnik, Jose
    Trivedi, Madhukar
    Tsui, Judith, I
    Williams, Arthur
    Wu, Li-Tzy
    Fiellin, David A.
    SUBSTANCE ABUSE, 2021, 42 (03) : 245 - 254
  • [48] The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016
    Mathur, Anthony
    Fernandez-Aviles, Francisco
    Dimmeler, Stefanie
    Hauskeller, Christine
    Janssens, Stefan
    Menasche, Philippe
    Wojakowski, Wojtek
    Martin, John F.
    Zeiher, Andreas
    EUROPEAN HEART JOURNAL, 2017, 38 (39) : 2930 - 2935
  • [49] Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine
    Wu, Alan H. B.
    Christenson, Robert H.
    Greene, Dina N.
    Jaffe, Allan S.
    Kavsak, Peter A.
    Ordonez-Llanos, Jordi
    Apple, Fred S.
    CLINICAL CHEMISTRY, 2018, 64 (04) : 645 - 655
  • [50] Clinical practice guidelines for the maintenance of patient physical safety in the intensive care unit: Use of restraining therapies - American College of Critical Care Medicine Task Force 2001-2002
    Maccioli, GA
    Dorman, T
    Brown, BR
    Mazuski, JE
    McLean, BA
    Kuszaj, JM
    Rosenbaum, SH
    Frankel, LR
    Devlin, JW
    Govert, JA
    Smith, B
    Peruzzi, WT
    CRITICAL CARE MEDICINE, 2003, 31 (11) : 2665 - 2676